

A. Personal Information

Name	Elisa Marabotto, MD, PhD
Business Address	Department of Internal Medicine Viale Benedetto XV, 6 16132 Genoa - Italy
Country of Residence	Italy
Date of birth	28 May 1979
Fiscal Code	MRBLSE79E68I480S
E-Mail Address	elisa.marabotto@unige.it

B. Education

1998	Liceo Scientifico, Istituto O. Grassi (Savona)
2004	Medical Degree University of Genoa, Genoa – Italy
2008	Postgraduate Degree in Gastroenterology University of Genoa, Genoa – Italy
2013	PhD in Medicina Interna, Autoimmunità e Malattie dell'Apparato Digerente University of Genoa, Genoa – Italy
2013-2014	Co.Li.pro University of Genoa, Genoa - Italy
2014-2020	Research Fellow University of Genoa, Genoa – Italy
2020-actually	Researcher (RTD-A) University of Genoa, Genoa - Italy

Research metrics (Web of Science)Publications: **95**H-index: **25**Total number of citations: **2409****C. Invited Lectures**

- 2014 Corso Rimini Informa
Corso ‘Complicanze gastrointestinali della Sclerosi Sistemica’
- 2015 Corso ‘Aggiornamenti in Gastroenterologia’
XV Congresso Trisocietario Ligure di Gastroenterologia
- 2016-2017 Relatore nel gruppo di lavoro: ‘Progetto FSC dalla Best Practice alla produzione scientifica: un'esperienza condivisa’ (09/06/2016-14/07/2016-22/09/2016-10/11/2016-08/06/2017)
- 2017 Tutor al XVII Congresso Nazionale Gismad
Corso ‘La malattia da reflusso gastroesofageo, dal sintomo alla corretta definizione dell'approccio diagnostico terapeutico’
XVII Congresso Ligure di Gastroenterologia
Relatore nel gruppo di lavoro: ‘Progetto FSC la ricerca al servizio della pratica clinica quotidiana nelle mici: un'esperienza condivisa’ (06/04/2017-21/09/2017-16/11/2017)
- 2018 Convegno ‘Hot Topics in Gastroenterologia ed Endoscopia Digestiva’
Congresso Trisocietario Ligure di Gastroenterologia
- 2019 Tutor al Congresso SINGEM
Congresso ‘Russamento ed apnee notturne: patologia emergente e malattia sociale’
Congresso Trisocietario Ligure di Gastroenterologia
- 2021 Relatore al 6° Congresso Interregionale AAIITO Liguria, Piemonte e Valle d’Aosta tenutosi al Palazzo della Meridiana di Genova il 24 e 25 Settembre 2021 con relazione dal titolo: ‘Esofagite eosinofila’
Partecipazione in qualità di Organizzatore al 2° Congresso Nazionale SINGEM e moderatore nella sessione dal titolo 'Dalla fisiopatologia alla terapia: la sfida dei non-responders': corso online dal 12 al 13 novembre 2021 a Bologna.
Relatore al corso di carattere scientifico FAD su Nutrizione e Malattia con obiettivo formativo: perfezionare ed aggiornare le conoscenze del

- partecipante nella tematica degli approcci nutrizionale e per la prevenzione e per il trattamento delle più comuni malattie croniche
 Relatore alla videoconferenza RES Colite ulcerosa e malattia di Crohn: nuovi orizzonti terapeutici
 Relatore alla videoconferenza RES Focus ON sulla gestione della malattia di Crohn
 Moderatore al Congresso SINGEM
- 2022
 Relatore al congresso FISMAD
 Relatore al congresso AGGEI
 Relatore al congresso SISME
- 2023
 Relatore al congresso FISMAD
 Relatore al congresso SINGEM
 Relatore al congresso AAIITO

E. **Bibliography**

Articles:

1. Testa E, Malfatti F, Milazzo S, Cordiviola C, Cotellessa T, **Marabotto E**, Giannini E, Ceppa P, Mamone M, Risso D, Testa R. Hyaluronic acid and aspartate aminotransferase levels normalized by liver function can reflect sinusoidal impairment in chronic liver disease. *Liver Int.* 2006 May;26(4):439-44.
2. Giannini EG, **Marabotto E**, Savarino V, Trevisani F, di Nolfo MA, Del Poggio P, Benvegnù L, Farinati F, Zoli M, Borzio F, Caturelli E, Chiaramonte M; Italian Liver Cancer (ITALICA) Group. Hepatocellular carcinoma in patients with cryptogenic cirrhosis. *Clin Gastroenterol Hepatol.* 2009 May;7(5):580-5.
3. Parodi A, Dulbecco P, Savarino E, Giannini EG, Bodini G, Corbo M, Isola L, De Conca S, **Marabotto E**, Savarino V. Positive glucose breath testing is more prevalent in patients with IBS-like symptoms compared with controls of similar age and gender distribution. *J Clin Gastroenterol.* 2009 Nov-Dec;43(10):962-6.
4. Savarino E, Tutuiian R, Zentilin P, Dulbecco P, Pohl D, **Marabotto E**, Parodi A, Sammito G, Gemignani L, Bodini G, Savarino V. Characteristics of reflux episodes and symptom association in patients with erosive esophagitis and nonerosive reflux disease: study using combined impedance-pH off therapy. *Am J Gastroenterol.* 2010 May;105(5):1053-61.
5. Savarino E, Zentilin P, Frazzoni M, Cuoco DL, Pohl D, Dulbecco P, **Marabotto E**, Sammito G, Gemignani L, Tutuiian R, Savarino V. Characteristics of gastro-esophageal reflux episodes in Barrett's esophagus, erosive esophagitis and healthy volunteers. *Neurogastroenterol Motil.* 2010 Oct;22(10):1061-e280.
6. Savarino E, **Marabotto E**, Zentilin P, Frazzoni M, Sammito G, Bonfanti D, Sconfienza L, Assandri L, Gemignani L, Malesci A, Savarino V. The added value of impedance-pH monitoring to

Rome III criteria in distinguishing functional heartburn from non-erosive reflux disease. *Dig Liver Dis.* 2011 Jul;43(7):542-7.

7. Savarino E, Gemignani L, Pohl D, Zentilin P, Dulbecco P, Assandri L, **Marabotto E**, Bonfanti D, Inferrera S, Fazio V, Malesci A, Tutuian R, Savarino V. Oesophageal motility and bolus transit abnormalities increase in parallel with the severity of gastro-oesophageal reflux disease. *Aliment Pharmacol Ther.* 2011 Aug;34(4):476-86.

8. Savarino E, Zentilin P, **Marabotto E**, Bonfanti D, Inferrera S, Assandri L, Sammito G, Gemignani L, Furnari M, Dulbecco P, Savarino V. Overweight is a risk factor for both erosive and non-erosive reflux disease. *Dig Liver Dis.* 2011 Dec;43(12):940-5.

9. Savarino E, Zentilin P, Mastracci L, Dulbecco P, **Marabotto E**, Gemignani L, Bruzzone L, de Bortoli N, Frigo AC, Fiocca R, Savarino V. Microscopic esophagitis distinguishes patients with non-erosive reflux disease from those with functional heartburn. *J Gastroenterol.* 2013 Apr;48(4):473-82.

10. Savarino E, Carbone R, **Marabotto E**, Furnari M, Sconfienza L, Ghio M, Zentilin P, Savarino V. Gastro-oesophageal reflux and gastric aspiration in idiopathic pulmonary fibrosis patients. *Eur Respir J.* 2013 Nov;42(5):1322-31.

11. Savarino E, Bodini G, Dulbecco P, Assandri L, Bruzzone L, Mazza F, Frigo AC, Fazio V, **Marabotto E**, Savarino V. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. *Am J Gastroenterol.* 2013 Nov;108(11):1731-42.

12. Savarino E, Savarino V, Fox M, Di Leo G, Furnari M, **Marabotto E**, Gemignani L, Bruzzone L, Moscatelli A, De Cassan C, Sardanelli F, Sconfienza LM. Measurement of oro-caecal transit time by magnetic resonance imaging. *Eur Radiol.* 2015 Jun;25(6):1579-87.

13. Tolone S, de Cassan C, de Bortoli N, Roman S, Galeazzi F, Salvador R, **Marabotto E**, Furnari M, Zentilin P, Marchi S, Bardini R, Sturniolo GC, Savarino V, Savarino E. Esophagogastric junction morphology is associated with a positive impedance-pH monitoring in patients with GERD. *Neurogastroenterol Motil.* 2015 Aug;27(8):1175-82.

14. Tolone S, De Bortoli N, **Marabotto E**, de Cassan C, Bodini G, Roman S, Furnari M, Savarino V, Docimo L, Savarino E. Esophagogastric junction contractility for clinical assessment in patients with GERD: a real added value? *Neurogastroenterol Motil.* 2015 Oct;27(10):1423-31.

15. Bodini G, Giannini EG, Furnari M, **Marabotto E**, Baldissarro I, Del Nero L, Assandri L, Moscatelli A, Savarino V, Savarino E. Comparison of Two Different Techniques to Assess Adalimumab Trough Levels in Patients with Crohn's Disease. *J Gastrointest Liver Dis.* 2015 Dec;24(4):451-6.

16. De Flora S, Camoirano A, Micale RT, La Maestra S, Savarino V, Zentilin P, **Marabotto E**, Suh M, Proctor DM. Reduction of hexavalent chromium by fasted and fed human gastric fluid. I. Chemical reduction and mitigation of mutagenicity. *Toxicol Appl Pharmacol.* 2016 Sep 1;306:113-9.

17. de Bortoli N, Frazzoni L, Savarino EV, Frazzoni M, Martinucci I, Jania A, Tolone S, Scagliarini M, Bellini M, **Marabotto E**, Furnari M, Bodini G, Russo S, Bertani L, Natali V, Fuccio L, Savarino V, Blandizzi C, Marchi S. Functional Heartburn Overlaps With Irritable Bowel Syndrome More Often than GERD. *Am J Gastroenterol.* 2016 Dec;111(12):1711-1717.

18. Bodini G, Giannini EG, De Maria C, Dulbecco P, Furnari M, **Marabotto E**, Savarino V, Savarino E. Anti-TNF therapy is able to stabilize bowel damage progression in patients with Crohn's disease. A study performed using the Lémann Index. *Dig Liver Dis.* 2017 Feb;49(2):175-180.

19. Zentilin P, Savarino V, **Marabotto E**, Murdaca G, Sulli A, Pizzorni C, Puppo F, Savarino E. Esophageal baseline impedance levels allow the identification of esophageal involvement in patients with systemic sclerosis. *Semin Arthritis Rheum*. 2018 Feb;47(4):569-574.
20. Giannini EG, Crespi M, Demarzo M, Bodini G, Furnari M, **Marabotto E**, Torre F, Zentilin P, Savarino V. Improvement in hepatitis C virus patients with advanced, compensated liver disease after sustained virological response to direct acting antivirals. *Eur J Clin Invest*. 2019 Mar;49(3):e13056.
21. Giannini EG, De Maria C, Crespi M, Demarzo MG, Fazio V, Grasso A, Torre F, Bodini G, **Marabotto E**, Furnari M. Course of oesophageal varices and performance of non-invasive predictors following Hepatitis C Virus clearance in compensated advanced chronic liver disease. *Eur J Clin Invest*. 2020 May;50(5):e13231.
22. Lenti MV, Savarino E, Mauro A, Penagini R, Racca F, Ghisa M, Laserra G, Merli S, Arsiè E, Longoni V, de Bortoli N, Sostilio A, **Marabotto E**, Ziola S, Vanoli A, Zingone F, Barberio B, Tolone S, Docimo L, Pellegatta G, Paoletti G, Ribolsi M, Repici A, Klersy C, Di Sabatino A. Diagnostic delay and misdiagnosis in eosinophilic oesophagitis. *Dig Liver Dis*. 2021 Dec;53(12):1632-1639.
23. **Marabotto E**, Ferone D, Sheijani AD, Vera L, Ziola S, Savarino E, Bodini G, Furnari M, Zentilin P, Savarino V, Giusti M, Navarro Rojas FA, Bagnasco M, Albertelli M, Giannini EG. Prevalence of Lactose Intolerance in Patients with Hashimoto Thyroiditis and Impact on LT4 Replacement Dose. *Nutrients*. 2022 Jul 22;14(15):3017.
24. Siboni S, Kristo I, Rogers BD, De Bortoli N, Hobson A, Louie B, Lee YY, Tee V, Tolone S, **Marabotto E**, Visaggi P, Haworth J, Ivy M, Greenan G, Facchini C, Masuda T, Yano F, Perry K, Balasubramanian G, Theodorou D, Triantafyllou T, Cusmai L, Boveri S, Schoppmann SF, Gyawali CP, Bonavina L. Improving the Diagnostic Yield of High-Resolution Esophageal Manometry for GERD: The "Straight Leg-Raise" International Study. *Clin Gastroenterol Hepatol*. 2023 Jul;21(7):1761-1770.
25. Ghisa M, Laserra G, **Marabotto E**, Ziola S, Tolone S, de Bortoli N, Frazzoni M, Mauro A, Penagini R, Savarino V, Barberio B, Giannini EG, Zentilin P, Gyawali CP, Savarino E. Achalasia and Obstructive Motor Disorders Are Not Uncommon in Patients With Eosinophilic Esophagitis. *Clin Gastroenterol Hepatol*. 2021 Aug;19(8):1554-1563.
26. Ribolsi M, Frazzoni M, **Marabotto E**, De Carlo G, Ziola S, Maniero D, Balestrieri P, Cicala M, Savarino E. Novel impedance-pH parameters are associated with proton pump inhibitor response in patients with inconclusive diagnosis of gastro-oesophageal reflux disease according to Lyon Consensus. *Aliment Pharmacol Ther*. 2021 Aug;54(4):412-418.
27. Giannini EG, Crespi M, Djahandideh A, Demarzo MG, Moscatelli A, Bodini G, Furnari M, **Marabotto E**, Plaz Torres MC, Zentilin P, Savarino V. Appropriateness of proton pump inhibitors treatment in clinical practice: Prospective evaluation in outpatients and perspective assessment of drug optimisation. *Dig Liver Dis*. 2020 Aug;52(8):862-868.
28. de Bortoli N, Gyawali CP, Frazzoni M, Tolone S, Frazzoni L, Vichi E, Visaggi P, Bellini M, **Marabotto E**, Penagini R, Savarino V, Marchi S, Savarino EV. Bile reflux in patients with nerd is associated with more severe heartburn and lower values of mean nocturnal baseline impedance and chemical clearance. *Neurogastroenterol Motil*. 2020 Dec;32(12):e13919.
29. Tack J, Vanuytsel T, Serra J, Accarino A, Stanghellini V, Barbara G; ESNM Consensus Group, the Leuven Consensus Group, the Italian Consensus Group, the Spanish Consensus Group on function testing in the COVID-19 pandemic era. European Society for Neurogastroenterology and Motility recommendations for conducting gastrointestinal motility and function testing in the recovery phase of the COVID-19 pandemic. *Neurogastroenterol Motil*. 2020 Jul;32(7):e13930.

30. Javier Molina-Infante, Carolina Gutierrez-Junquera, Edoardo Savarino, Roberto Penagini, Ines Modolell, Ottavia Bartolo, Alicia Prieto-García, Aurelio Mauro, Javier Alcedo, Antonia Perelló, Carlos Guarner-Argente, Noelia Alcaide, Ana M Vegas, Patricia Barros-García, Marianne Murzi-Pulgar, Monica Perona, Javier P Gisbert, Alfredo J Lucendo; Upper GI Tract Study Group from the Spanish Gastroenterological Association (AEG) Galera, A.P. Helicobacter pylori infection does not protect against eosinophilic esophagitis: results from a large multicenter case-control study. *American Journal of Gastroenterology*, 2018, 113(7), pp. 972–979
31. Marten Canavesio Y, Pasta A, Calabrese F, Alessandri E, Cutolo M, Paolino S, Pizzorni C, Sulli A, Savarino V, Giannini EG, Zentilin P, Bodini G, Furnari M, Savarino E, **Marabotto E**. Association between esophageal motor disorders and pulmonary involvement in patients affected by systemic sclerosis: a retrospective study. *Rheumatol Int*. 2023 Aug 5

Reviews:

1. Savarino E, Ghio M, **Marabotto E**, Zentilin P, Sammito G, Cittadini G, Sconfienza L, Murolo C, Gemignani L, Indiveri F, Savarino V. [Possible connection between gastroesophageal reflux and interstitial pulmonary fibrosis in patients with systemic sclerosis]. *Recenti Prog Med*. 2009 Nov;100(11):512-6.
2. Martinucci I, de Bortoli N, Giacchino M, Bodini G, **Marabotto E**, Marchi S, Savarino V, Savarino E. Esophageal motility abnormalities in gastroesophageal reflux disease. *World J Gastrointest Pharmacol Ther*. 2014 May 6;5(2):86-96.
3. Furnari M, de Bortoli N, Martinucci I, Bodini G, Revelli M, **Marabotto E**, Moscatelli A, Del Nero L, Savarino E, Giannini EG, Savarino V. Optimal management of constipation associated with irritable bowel syndrome. *Ther Clin Risk Manag*. 2015 May 30;11:691-703. eCollection 2015.
4. Savarino E, Martinucci I, Furnari M, Romana C, Pellegatta G, Moscatelli A, Bodini G, **Marabotto E**, Savarino V, de Bortoli N, Blandizzi C. Vonoprazan for treatment of gastroesophageal reflux: pharmacodynamic and pharmacokinetic considerations. *Expert Opin Drug Metab Toxicol*. 2016 Nov;12(11):1333-1341.
5. Savarino E, de Bortoli N, De Cassan C, Della Coletta M, Bartolo O, Furnari M, Ottonello, **Marabotto E**, Bodini G, Savarino V. The natural history of gastro-esophageal reflux disease: a comprehensive review. *Dis Esophagus*. 2017 Feb 1;30(2):1-9.
6. Savarino E, **Marabotto E**, Bodini G, Pellegatta G, Coppo C, Giambruno E, Brunacci M, Zentilin P, Savarino V. Epidemiology and natural history of gastroesophageal reflux disease. *Minerva Gastroenterol Dietol*. 2017 Sep;63(3):175-183.
7. Zentilin P, **Marabotto E**, Pellegatta G, Coppo C, Furnari M, Savarino E, Savarino V. Complexity and diversity of gastroesophageal reflux disease phenotypes. *Minerva Gastroenterol Dietol*. 2017 Sep;63(3):198-204.
8. Martinucci I, Blandizzi C, Bodini G, **Marabotto E**, Savarino V, Marchi S, de Bortoli N, Savarino E. Vonoprazan fumarate for the management of acid-related diseases. *Expert Opin Pharmacother*. 2017 Aug;18(11):1145-1152.
9. Savarino E, Zentilin P, **Marabotto E**, Bodini G, Della Coletta M, Frazzoni M, de Bortoli N, Martinucci I, Tolone S, Pellegatta G, Savarino V. A review of pharmacotherapy for treating gastroesophageal reflux disease (GERD). *Expert Opin Pharmacother*. 2017 Sep;18(13):1333-1343.

10. Savarino E, Zentilin P, **Marabotto E**, Pellegatta G, Coppo C, Brunacci M, Dulbecco P, Savarino V. Drugs for improving esophageal mucosa defense: where are we now and where are we going? *Ann Gastroenterol*. 2017;30(6):585-591.
11. Savarino E, **Marabotto E**, Savarino V. Effects of bariatric surgery on the esophagus. *Curr Opin Gastroenterol*. 2018 Jul;34(4):243-248.
12. Savarino V, **Marabotto E**, Zentilin P, Furnari M, Bodini G, De Maria C, Pellegatta G, Coppo C, Savarino E. The appropriate use of proton-pump inhibitors. *Minerva Med*. 2018 Oct;109(5):386-399.
13. Savarino E, **Marabotto E**, Zentilin P, Furnari M, Bodini G, Pellegatta G, Lorenzon G, Della Coletta M, Ghisa M, Coppo C, Marinelli C, Savarino V. A safety review of proton pump inhibitors to treat acid-related digestive diseases. *Expert Opin Drug Saf*. 2018 Aug;17(8):785-794.
14. Savarino V, **Marabotto E**, Zentilin P, Furnari M, Bodini G, De Maria C, Pellegatta G, Coppo C, Savarino E. Proton pump inhibitors: use and misuse in the clinical setting. *Expert Rev Clin Pharmacol*. 2018 Nov;11(11):1123-1134.
15. Savarino E, Bertani L, Ceccarelli L, Bodini G, Zingone F, Buda A, Facchin S, Lorenzon G, Marchi S, **Marabotto E**, De Bortoli N, Savarino V, Costa F, Blandizzi C. Antimicrobial treatment with the fixed-dose antibiotic combination RHB-104 for *Mycobacterium avium* subspecies paratuberculosis in Crohn's disease: pharmacological and clinical implications. *Expert Opin Biol Ther*. 2019 Feb;19(2):79-88.
16. Savarino E, **Marabotto E**, Bodini G, Furnari M, Della Coletta M, Ghisa M, Barberio B, Frazzoni M, De Bortoli N, Zentilin P, Pellegatta G, Tolone S, Ottonello A, Savarino V. Advancements in the use of manometry and impedance testing for esophageal functional disorders. *Expert Rev Gastroenterol Hepatol*. 2019 May;13(5):425-435.
17. Ghisa M, Della Coletta M, Barbuscio I, **Marabotto E**, Barberio B, Frazzoni M, De Bortoli N, Zentilin P, Tolone S, Ottonello A, Lorenzon G, Savarino V, Savarino E. Updates in the field of non-esophageal gastroesophageal reflux disorder. *Expert Rev Gastroenterol Hepatol*. 2019 Sep;13(9):827-838.
18. Plaz Torres MC, Aghemo A, Lleo A, Bodini G, Furnari M, **Marabotto E**, Miele L, Giannini EG. Mediterranean Diet and NAFLD: What We Know and Questions That Still Need to Be Answered. *Nutrients*. 2019 Dec 5;11(12). pii: E2971.
19. Savarino V, **Marabotto E**, Zentilin P, Furnari M, Bodini G, De Maria C, Tolone S, De Bortoli N, Frazzoni M, Savarino E. Pathophysiology, diagnosis, and pharmacological treatment of gastro-esophageal reflux disease. *Expert Rev Clin Pharmacol*. 2020 Apr;13(4):437-449.
20. **Marabotto E**, Ziola S, Savarino V, Giannini EG, Furnari M, Bodini G, Zingone F, Ghisa M, Barberio B, Zentilin P, Savarino E. Vonoprazan Fumarate for the Treatment of Gastric Ulcers: A Short Review on Emerging Data. *Clin Exp Gastroenterol*. 2020 Apr 15;13:99-104. doi: 10.2147/CEG.S228352. eCollection 2020. Review.
21. Plaz Torres MC, Jaffe A, Perry R, **Marabotto E**, Strazzabosco M, Giannini EG. Diabetes medications and risk of HCC. *Hepatology*. 2022 Dec;76(6):1880-1897.
22. Savarino V, **Marabotto E**, Zentilin P, Demarzo MG, de Bortoli N, Savarino E. Pharmacological Management of Gastro-Esophageal Reflux Disease: An Update of the State-of-the-Art. *Drug Des Devel Ther*. 2021 Apr 19;15:1609-1621.
23. Ghisa M, Laserra G, Maniero D, **Marabotto E**, Barberio B, Pelizzaro F, Barbuscio I, Zingone F, Savarino V, Savarino E. Eosinophilic esophagitis: from pathophysiology to management. *Minerva Gastroenterol (Torino)*. 2022 Mar;68(1):40-48.

24. **Marabotto E**, Giannini EG, Zentilin P, Ziola S, Djahandideh Sheijani A, Savarino E, Savarino V. Pharmacotherapies in eosinophilic esophagitis: state of the art. *Minerva Gastroenterol (Torino)*. 2022 Mar;68(1):69-76.
25. **Marabotto E**, Pellegatta G, Sheijani AD, Ziola S, Zentilin P, De Marzo MG, Giannini EG, Ghisa M, Barberio B, Scarpa M, Angriman I, Fassan M, Savarino V, Savarino E. Prevention Strategies for Esophageal Cancer-An Expert Review. *Cancers (Basel)*. 2021 May 1;13(9):2183.
26. Savarino V, **Marabotto E**, Zentilin P, Demarzo MG, Pellegatta G, Frazzoni M, De Bortoli N, Tolone S, Giannini EG, Savarino E. Esophageal reflux hypersensitivity: Non-GERD or still GERD? *Dig Liver Dis*. 2020 Dec;52(12):1413-1420.
27. Savarino E, **Marabotto E**, Savarino V. Recent insights on functional heartburn and reflux hypersensitivity. *Curr Opin Gastroenterol*. 2022 Jul 1;38(4):417-422.
28. Ghisa M, Barberio B, Savarino V, **Marabotto E**, Ribolsi M, Bodini G, Zingone F, Frazzoni M, Savarino E. The Lyon Consensus: Does It Differ From the Previous Ones? *Neurogastroenterol Motil*. 2020 Jul 30;26(3):311-321.
29. Visaggi P, Mariani L, Pardi V, Rosi EM, Pugno C, Bellini M, Zingone F, Ghisa M, **Marabotto E**, Giannini EG, Savarino V, Marchi S, Savarino EV, de Bortoli N. Dietary Management of Eosinophilic Esophagitis: Tailoring the Approach. *Nutrients*. 2021 May 12;13(5):1630.
30. **Marabotto E**, Savarino V, Savarino E. Towards a more precise classification of esophageal motility disorders in patients with systemic sclerosis. *Neurogastroenterol Motil*. 2022 Jul;34(7):e14416.
31. **Marabotto E**, Savarino V, Ghisa M, Frazzoni M, Ribolsi M, Barberio B, Savarino E. Advancements in the use of 24-hour impedance-pH monitoring for GERD diagnosis. *Curr Opin Pharmacol*. 2022 Aug;65:102264.
32. **Marabotto E**, Kayali S, Buccilli S, Levo F, Bodini G, Giannini EG, Savarino V, Savarino EV. Colorectal Cancer in Inflammatory Bowel Diseases: Epidemiology and Prevention: A Review. *Cancers (Basel)*. 2022 Aug 31;14(17):4254.
33. Visaggi P, Ghisa M, Barberio B, **Marabotto E**, de Bortoli N, Savarino E. Systematic Review: esophageal motility patterns in patients with eosinophilic esophagitis. *Dig Liver Dis*. 2022 Sep;54(9):1143-1152.
34. Savarino V, Antonioli L, Fornai M, **Marabotto E**, Demarzo MG, Zingone F, Ghisa M, Barberio B, Zentilin P, Ribolsi M, Savarino E. An update of pharmacology, efficacy, and safety of vonoprazan in acid-related disorders. *Expert Rev Gastroenterol Hepatol*. 2022 May;16(5):401-410.
35. Savarino E, Frazzoni M, **Marabotto E**, Zentilin P, Iovino P, Costantini M, Tolone S, Battaglia E, Cicala M, Usai-Satta P, de Bortoli N, Penagini R, Savarino V. A SIGE-SINGEM-AIGO technical review on the clinical use of esophageal reflux monitoring. *Dig Liver Dis*. 2020 Sep;52(9):966-980.
36. Savarino V, **Marabotto E**, Furnari M, Zingone F, Zentilin P, Savarino E. Latest insights into the hot question of proton pump inhibitor safety - a narrative review. *Dig Liver Dis*. 2020 Aug;52(8):842-852.
37. Plaz Torres MC, Bodini G, Furnari M, **Marabotto E**, Zentilin P, Strazzabosco M, Giannini EG. Cancers (Basel). Surveillance for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease: Universal or Selective? 2020 May 31;12(6):1422.
38. Plaz Torres MC, Bodini G, Furnari M, **Marabotto E**, Zentilin P, Giannini EG. Nuts and Non-Alcoholic Fatty Liver Disease: Are Nuts Safe for Patients with Fatty Liver Disease? *Nutrients*. 2020 Nov 1;12(11):3363.

39. Visaggi P, Ghisa M, **Marabotto E**, Venturini A, Stefani Donati D, Bellini M, Savarino V, de Bortoli N, Savarino E. Esophageal dysmotility in patients with eosinophilic esophagitis: pathogenesis, assessment tools, manometric characteristics, and clinical implications. *Esophagus*. 2023 Jan;20(1):29-38.
40. Savarino E, Carbone R, **Marabotto E**, Inferrera S, Gemignani L, Malesci A, Savarino V. Gastroesophageal reflux and idiopathic pulmonary fibrosis-new evidences of a causal relationship. *Annals of Respiratory Medicine*. 2 (2012) 39–46.
41. Savarino V, **Marabotto E**, Zentilin P, De Bortoli N, Visaggi P, Furnari M, Bodini G, Giannini E, Savarino E. How safe are heartburn medications and who should use them? *Expert Opin Drug Saf*. 2023 Jul-Dec;22(8):643-652.

Letters:

1. Savarino E, Zentilin P, Furnari M, Bodini G, **Marabotto E**, Savarino V. Not All Patients With Non-erosive Reflux Disease Share Psychological Distress as Main Mechanism of Disease. *J Neurogastroenterol Motil*. 2014 Jan;20(1):129-30.
2. Savarino E, **Marabotto E**, Bartolo O, de Cassan C. Comment on "impairment of chemical clearance is relevant to the pathogenesis of refractory reflux oesophagitis" by Marzio Frazzoni et al. [*Digestive and Liver Disease* 2014;46:596-602]. *Dig Liver Dis*. 2014 Nov;46(11):1052.
3. Bodini G, Savarino V, **Marabotto E**, Savarino E. Anti-Tumor Necrosis Factor Antibodies for Prevention of Crohn's Disease Recurrence After Surgery: More Than a Hope. *Clin Gastroenterol Hepatol*. 2015 Oct;13(10):1856.
4. Savarino E, Bodini G, **Marabotto E**, Savarino V. Impedance-detected Symptom Association and Number of Reflux Episodes as Pre-treatment Parameters That Predict Outcomes of Gastroesophageal Reflux Disease Patients. *J Neurogastroenterol Motil*. 2015 Mar 30;21(2):292-3.
5. Savarino E, Zentilin P, **Marabotto E**, Savarino V. Pathophysiological Studies Are Mandatory to Understand the Benefit of Proton Pump Inhibitors in Patients with Idiopathic Pulmonary Fibrosis. *J Neurogastroenterol Motil*. 2016 Oct 30;22(4):710-711.
6. Savarino E, Zentilin P, **Marabotto E**, Savarino V. Relevance of Measuring Substances in Bronchoalveolar Lavage Fluid for Detecting Aspiration-associated Extraesophageal Reflux Disease. *J Neurogastroenterol Motil*. 2017 Apr 30;23(2):318-319.
7. Giannini EG, Bodini G, Furnari M, **Marabotto E**. NASH-related and cryptogenic cirrhosis similarities extend beyond cirrhosis. *J Hepatol*. 2018 Oct;69(4):972-973.
8. Giannini EG, Bodini G, Furnari M, **Marabotto E**. Bleeding after paracentesis in patients with decompensated cirrhosis and acute kidney injury: The perfect storm. *Liver Int*. 2018 Nov;38(11):2101.
9. Crespi M, Ghidotti I, Bodini G, Furnari M, **Marabotto E**, Giannini EG. Harmonising proton pump inhibitors treatment in the specialist setting following the SIGE recommendations. *Dig Liver Dis*. 2019 Jan;51(1):173-174.
10. **Marabotto E**, Furnari M, Giannini EG, Savarino V, Savarino E. Letter: it is time to adopt new objective parameters to accurately identify patients with functional heartburn. *Aliment Pharmacol Ther*. 2018 Jul;48(1):107-108.
11. Giannini EG, Bodini G, Furnari M, **Marabotto E**. A Closer Look at Factors Associated With Bleeding in Cirrhotic Patients. *Am J Gastroenterol*. 2019 Feb;114(2):364-365.

12. Giannini EG, Crespi M, Demarzo M, Bodini G, Furnari M, **Marabotto E**, Torre F. Regression of Fibrosis After Direct-acting Antivirals Treatment of Patients with Hepatitis C Virus Cirrhosis: Transposability to Nondecompensated Patients. *J Clin Exp Hepatol*. 2019 Jul-Aug;9(4):546.
13. Giannini EG, Bodini G, Furnari M, **Marabotto E**. Hepatocellular Carcinoma Intermediate Stage Subclassification Systems: One, None, and One Hundred Thousand. *Liver Cancer*. 2019 Nov;8(6):524-526.
14. Savarino V, **Marabotto E**, Zentilin P, Savarino E. The prevention of NSAID-induced gastric ulcers is a firmly established PPI indication. *Expert Rev Clin Pharmacol*. 2019 Nov;12(11):1011-1012.
15. Cacciato V, Casagrande E, Bodini G, Furnari M, **Marabotto E**, Grillo F, Giannini EG. Eradication of hepatitis C virus infection disclosing a previously hidden, underlying autoimmune hepatitis: Autoimmune hepatitis and HCV. *Ann Hepatol*. 2020 Mar - Apr;19(2):222-225.
16. Ribolsi M, Frazzoni M, **Marabotto E**, Cicala M, Savarino E. Editorial: inconclusive diagnosis of GERD: are new parameters in impedance-pHmetry ready for clinical use? Authors' reply. *Aliment Pharmacol Ther*. 2021 Aug;54(4):498-499.
17. **Marabotto E**, Ziola S, Sheijani AD, Giannini EG. COVID-19 and liver disease: Not all evil comes to harm. *Liver Int*. 2021 Jan;41(1):237-238.
18. **Marabotto E**, Savarino E, de Bortoli N, Giannini EG. Refractoriness to Treatment Suggests That Clinical Evaluation Should Go Beyond the Diagnosis of Reflux Disease. *Clin Gastroenterol Hepatol*. 2021 May;19(5):1077-1078.
19. Papadia FS, **Marabotto E**, Mascherini M, Rubartelli A, Camerini G, Giannini EG. Sleeve gastrectomy may double the risk of esophageal adenocarcinoma in morbidly obese patients. *Surg Obes Relat Dis*. 2021 May;17(5):1029-1030.
20. Giannini EG, Bodini G, Furnari M, **Marabotto E**. Proactive Measures Aimed at Improving Appropriateness of Use of Proton Pump Inhibitors in Clinical Practice. *Clin Gastroenterol Hepatol*. 2021 Feb;19(2):410.
21. Giannini EG, Bodini G, **Marabotto E**, Furnari M. Applicability of Parameters for the Noninvasive Diagnosis of Esophageal Varices Needing Treatment to Hepatitis C Virus-Cured Patients. *Clin Infect Dis*. 2021 May 18;72(10):1862-1863.
22. Giannini EG, Bodini G, **Marabotto E**, Plaz Torres MC, Zentilin P, Furnari M. Risk factors for bleeding following oesophageal band ligation: Providing further evidence to ameliorate clinical practice. *Dig Liver Dis*. 2020 Jul;52(7):792-793.
23. Plaz Torres MC, Jaffe A, Perry R, **Marabotto E**, Strazzabosco M, Giannini EG. Reply: Novel antidiabetic drugs and the risk for HCC. What else to expect from these "wonderful" drug classes? *Hepatology*. 2023 Jun 1;77(6):E184-E185.